ID   ITPK1_HUMAN             Reviewed;         414 AA.
AC   Q13572; Q9BTL6; Q9H2E7;
DT   06-DEC-2005, integrated into UniProtKB/Swiss-Prot.
DT   06-DEC-2005, sequence version 2.
DT   22-JUL-2015, entry version 129.
DE   RecName: Full=Inositol-tetrakisphosphate 1-kinase;
DE            EC=2.7.1.134;
DE   AltName: Full=Inositol 1,3,4-trisphosphate 5/6-kinase;
DE            Short=Inositol-triphosphate 5/6-kinase;
DE            Short=Ins(1,3,4)P(3) 5/6-kinase;
DE            EC=2.7.1.159;
GN   Name=ITPK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), ENZYME ACTIVITY, COFACTOR, AND
RP   TISSUE SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=8662638; DOI=10.1074/jbc.271.20.11904;
RA   Wilson M.P., Majerus P.W.;
RT   "Isolation of inositol 1,3,4-trisphosphate 5/6-kinase, cDNA cloning
RT   and expression of the recombinant enzyme.";
RL   J. Biol. Chem. 271:11904-11910(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), ENZYME ACTIVITY, AND
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=11042108; DOI=10.1042/0264-6021:3510551;
RA   Yang X., Shears S.B.;
RT   "Multitasking in signal transduction by a promiscuous human
RT   Ins(3,4,5,6)P(4) 1-kinase/Ins(1,3,4)P(3) 5/6-kinase.";
RL   Biochem. J. 351:551-555(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Eye, and Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   PUTATIVE FUNCTION AS PROTEIN KINASE.
RX   PubMed=11533064; DOI=10.1074/jbc.M106605200;
RA   Wilson M.P., Sun Y., Cao L., Majerus P.W.;
RT   "Inositol 1,3,4-trisphosphate 5/6-kinase is a protein kinase that
RT   phosphorylates the transcription factors c-Jun and ATF-2.";
RL   J. Biol. Chem. 276:40998-41004(2001).
RN   [5]
RP   FUNCTION.
RX   PubMed=11909533; DOI=10.1016/S0960-9822(02)00713-3;
RA   Ho M.W.Y., Yang X., Carew M.A., Zhang T., Hua L., Kwon Y.-U.,
RA   Chung S.-K., Adelt S., Vogel G., Riley A.M., Potter B.V.L.,
RA   Shears S.B.;
RT   "Regulation of Ins(3,4,5,6)P(4) signaling by a reversible
RT   kinase/phosphatase.";
RL   Curr. Biol. 12:477-482(2002).
RN   [6]
RP   INTERACTION WITH GPS1.
RX   PubMed=12324474; DOI=10.1074/jbc.M208709200;
RA   Sun Y., Wilson M.P., Majerus P.W.;
RT   "Inositol 1,3,4-trisphosphate 5/6-kinase associates with the COP9
RT   signalosome by binding to CSN1.";
RL   J. Biol. Chem. 277:45759-45764(2002).
RN   [7]
RP   FUNCTION.
RX   PubMed=12925536; DOI=10.1074/jbc.M300674200;
RA   Sun Y., Mochizuki Y., Majerus P.W.;
RT   "Inositol 1,3,4-trisphosphate 5/6-kinase inhibits tumor necrosis
RT   factor-induced apoptosis.";
RL   J. Biol. Chem. 278:43645-43653(2003).
RN   [8]
RP   MUTAGENESIS OF ARG-106; LYS-157; GLY-163; ASP-281; ASP-295 AND
RP   ASN-297.
RX   PubMed=15762844; DOI=10.1042/BJ20050297;
RA   Qian X., Mitchell J., Wei S.J., Williams J., Petrovich R.M.,
RA   Shears S.B.;
RT   "The Ins(1,3,4)P3 5/6-kinase/Ins(3,4,5,6)P4 1-kinase is not a protein
RT   kinase.";
RL   Biochem. J. 389:389-395(2005).
RN   [9]
RP   MUTAGENESIS OF LYS-18; HIS-58; LYS-59; ARG-106; HIS-162; GLY-163;
RP   HIS-167; GLN-188; HIS-193; LYS-199; ARG-212; SER-214; LEU-215; ASN-297
RP   AND GLY-301.
RX   PubMed=15837423; DOI=10.1016/j.molcel.2005.03.016;
RA   Miller G.J., Wilson M.P., Majerus P.W., Hurley J.H.;
RT   "Specificity determinants in inositol polyphosphate synthesis: crystal
RT   structure of inositol 1,3,4-trisphosphate 5/6-kinase.";
RL   Mol. Cell 18:201-212(2005).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [12]
RP   ACETYLATION AT LYS-340; LYS-383 AND LYS-410.
RX   PubMed=22308441; DOI=10.1073/pnas.1119740109;
RA   Zhang C., Majerus P.W., Wilson M.P.;
RT   "Regulation of inositol 1,3,4-trisphosphate 5/6-kinase (ITPK1) by
RT   reversible lysine acetylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:2290-2295(2012).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 1-335 IN COMPLEXES WITH
RP   MANGANESE; ATP ANALOG AND ADP, FUNCTION, AND SUBUNIT.
RX   PubMed=17616525; DOI=10.1074/jbc.M703121200;
RA   Chamberlain P.P., Qian X., Stiles A.R., Cho J., Jones D.H.,
RA   Lesley S.A., Grabau E.A., Shears S.B., Spraggon G.;
RT   "Integration of inositol phosphate signaling pathways via human
RT   ITPK1.";
RL   J. Biol. Chem. 282:28117-28125(2007).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (2.01 ANGSTROMS) OF 1-327.
RG   Structural genomics consortium (SGC);
RT   "Structure of human inositol 1,3,4-trisphosphate 5/6-kinase.";
RL   Submitted (FEB-2007) to the PDB data bank.
CC   -!- FUNCTION: Kinase that can phosphorylate various inositol
CC       polyphosphate such as Ins(3,4,5,6)P4 or Ins(1,3,4)P3.
CC       Phosphorylates Ins(3,4,5,6)P4 at position 1 to form
CC       Ins(1,3,4,5,6)P5. This reaction is thought to have regulatory
CC       importance, since Ins(3,4,5,6)P4 is an inhibitor of plasma
CC       membrane Ca(2+)-activated Cl(-) channels, while Ins(1,3,4,5,6)P5
CC       is not. Also phosphorylates Ins(1,3,4)P3 on O-5 and O-6 to form
CC       Ins(1,3,4,6)P4, an essential molecule in the hexakisphosphate
CC       (InsP6) pathway. Also acts as an inositol polyphosphate
CC       phosphatase that dephosphorylate Ins(1,3,4,5)P4 and Ins(1,3,4,6)P4
CC       to Ins(1,3,4)P3, and Ins(1,3,4,5,6)P5 to Ins(3,4,5,6)P4. May also
CC       act as an isomerase that interconverts the inositol
CC       tetrakisphosphate isomers Ins(1,3,4,5)P4 and Ins(1,3,4,6)P4 in the
CC       presence of ADP and magnesium. Probably acts as the rate-limiting
CC       enzyme of the InsP6 pathway. Modifies TNF-alpha-induced apoptosis
CC       by interfering with the activation of TNFRSF1A-associated death
CC       domain. {ECO:0000269|PubMed:11909533, ECO:0000269|PubMed:12925536,
CC       ECO:0000269|PubMed:17616525}.
CC   -!- CATALYTIC ACTIVITY: ATP + 1D-myo-inositol 3,4,5,6-
CC       tetrakisphosphate = ADP + 1D-myo-inositol 1,3,4,5,6-
CC       pentakisphosphate.
CC   -!- CATALYTIC ACTIVITY: ATP + 1D-myo-inositol 1,3,4-trisphosphate =
CC       ADP + 1D-myo-inositol 1,3,4,5-tetrakisphosphate.
CC   -!- CATALYTIC ACTIVITY: ATP + 1D-myo-inositol 1,3,4-trisphosphate =
CC       ADP + 1D-myo-inositol 1,3,4,6-tetrakisphosphate.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:8662638};
CC       Note=Binds 2 magnesium ions per subunit.
CC       {ECO:0000269|PubMed:8662638};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.3 uM for Ins(1,3,4)P3 {ECO:0000269|PubMed:11042108};
CC         KM=0.1 uM for Ins(3,4,5,6)P4 {ECO:0000269|PubMed:11042108};
CC         Vmax=320 pmol/min/ug enzyme with Ins(1,3,4)P3 as substrate
CC         {ECO:0000269|PubMed:11042108};
CC         Vmax=780 pmol/min/ug enzyme enzyme with Ins(3,4,5,6)P4 as
CC         substrate {ECO:0000269|PubMed:11042108};
CC   -!- SUBUNIT: Monomer. Interacts with GPS1/COPS1.
CC       {ECO:0000269|PubMed:12324474, ECO:0000269|PubMed:17616525}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q13572-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q13572-2; Sequence=VSP_016478, VSP_016479;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed in brain > heart > skeletal muscle =
CC       kidney = pancreas = liver = placenta > lung. In brain, it is
CC       expressed in cerebellum, cerebral cortex, medulla, spinal cord,
CC       occipital lobe, frontal lobe, temporal lobe and putamen.
CC       {ECO:0000269|PubMed:8662638}.
CC   -!- PTM: Acetylation by EP300 and CREBBP destabilizes ITPK1, and down-
CC       regulates enzymatic activity. Deacetylated by SIRT1.
CC       {ECO:0000269|PubMed:22308441}.
CC   -!- SIMILARITY: Belongs to the ITPK1 family. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 ATP-grasp domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00409}.
CC   -!- CAUTION: PubMed:11533064 detected some protein kinase activity and
CC       ability to phosphorylate transcription factors c-jun/JUN and ATF2.
CC       However, PubMed:15762844 showed that it does not have protein
CC       kinase activity. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U51336; AAC50483.1; -; mRNA.
DR   EMBL; AF279372; AAG44835.1; -; mRNA.
DR   EMBL; BC003622; AAH03622.1; -; mRNA.
DR   EMBL; BC007428; AAH07428.1; -; mRNA.
DR   EMBL; BC018192; AAH18192.1; -; mRNA.
DR   CCDS; CCDS45157.1; -. [Q13572-2]
DR   CCDS; CCDS9907.1; -. [Q13572-1]
DR   RefSeq; NP_001136065.1; NM_001142593.1. [Q13572-1]
DR   RefSeq; NP_001136066.1; NM_001142594.1. [Q13572-2]
DR   RefSeq; NP_055031.2; NM_014216.4. [Q13572-1]
DR   UniGene; Hs.308122; -.
DR   PDB; 2ODT; X-ray; 2.01 A; X=1-327.
DR   PDB; 2Q7D; X-ray; 1.60 A; A/B=1-335.
DR   PDB; 2QB5; X-ray; 1.80 A; A/B=1-335.
DR   PDBsum; 2ODT; -.
DR   PDBsum; 2Q7D; -.
DR   PDBsum; 2QB5; -.
DR   ProteinModelPortal; Q13572; -.
DR   SMR; Q13572; 6-322.
DR   BioGrid; 109910; 10.
DR   DIP; DIP-60016N; -.
DR   IntAct; Q13572; 2.
DR   MINT; MINT-1463374; -.
DR   STRING; 9606.ENSP00000267615; -.
DR   ChEMBL; CHEMBL1938220; -.
DR   PhosphoSite; Q13572; -.
DR   BioMuta; ITPK1; -.
DR   DMDM; 83288249; -.
DR   MaxQB; Q13572; -.
DR   PaxDb; Q13572; -.
DR   PRIDE; Q13572; -.
DR   DNASU; 3705; -.
DR   Ensembl; ENST00000267615; ENSP00000267615; ENSG00000100605.
DR   Ensembl; ENST00000354313; ENSP00000346272; ENSG00000100605. [Q13572-2]
DR   Ensembl; ENST00000556603; ENSP00000451091; ENSG00000100605.
DR   Ensembl; ENST00000614271; ENSP00000483767; ENSG00000274958.
DR   Ensembl; ENST00000617836; ENSP00000480918; ENSG00000274958. [Q13572-2]
DR   Ensembl; ENST00000626153; ENSP00000486991; ENSG00000274958.
DR   GeneID; 3705; -.
DR   KEGG; hsa:3705; -.
DR   UCSC; uc001ybe.2; human. [Q13572-2]
DR   UCSC; uc001ybf.3; human. [Q13572-1]
DR   CTD; 3705; -.
DR   GeneCards; GC14M093403; -.
DR   H-InvDB; HIX0037938; -.
DR   HGNC; HGNC:6177; ITPK1.
DR   HPA; HPA055230; -.
DR   MIM; 601838; gene.
DR   neXtProt; NX_Q13572; -.
DR   PharmGKB; PA29974; -.
DR   eggNOG; NOG85132; -.
DR   GeneTree; ENSGT00390000001278; -.
DR   HOVERGEN; HBG079462; -.
DR   InParanoid; Q13572; -.
DR   KO; K00913; -.
DR   OMA; CSASPGC; -.
DR   OrthoDB; EOG70GMG7; -.
DR   PhylomeDB; Q13572; -.
DR   TreeFam; TF329288; -.
DR   BioCyc; MetaCyc:HS02123-MONOMER; -.
DR   BRENDA; 2.7.1.134; 2681.
DR   BRENDA; 2.7.1.159; 2681.
DR   Reactome; REACT_150188; Synthesis of pyrophosphates in the cytosol.
DR   Reactome; REACT_150312; Synthesis of IP3 and IP4 in the cytosol.
DR   Reactome; REACT_24970; Factors involved in megakaryocyte development and platelet production.
DR   SABIO-RK; Q13572; -.
DR   ChiTaRS; ITPK1; human.
DR   EvolutionaryTrace; Q13572; -.
DR   GeneWiki; ITPK1; -.
DR   GenomeRNAi; 3705; -.
DR   NextBio; 14521; -.
DR   PRO; PR:Q13572; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   Bgee; Q13572; -.
DR   ExpressionAtlas; Q13572; baseline and differential.
DR   Genevisible; Q13572; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0003824; F:catalytic activity; TAS:ProtInc.
DR   GO; GO:0047325; F:inositol tetrakisphosphate 1-kinase activity; TAS:Reactome.
DR   GO; GO:0052825; F:inositol-1,3,4,5,6-pentakisphosphate 1-phosphatase activity; TAS:Reactome.
DR   GO; GO:0052831; F:inositol-1,3,4,6-tetrakisphosphate 1-phosphatase activity; TAS:Reactome.
DR   GO; GO:0052830; F:inositol-1,3,4,6-tetrakisphosphate 6-phosphatase activity; TAS:Reactome.
DR   GO; GO:0052726; F:inositol-1,3,4-trisphosphate 5-kinase activity; TAS:Reactome.
DR   GO; GO:0052725; F:inositol-1,3,4-trisphosphate 6-kinase activity; TAS:Reactome.
DR   GO; GO:0052835; F:inositol-3,4,6-trisphosphate 1-kinase activity; TAS:Reactome.
DR   GO; GO:0016853; F:isomerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:InterPro.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0016311; P:dephosphorylation; TAS:GOC.
DR   GO; GO:0043647; P:inositol phosphate metabolic process; TAS:Reactome.
DR   GO; GO:0032957; P:inositol trisphosphate metabolic process; IEA:InterPro.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0044281; P:small molecule metabolic process; TAS:Reactome.
DR   InterPro; IPR011761; ATP-grasp.
DR   InterPro; IPR008656; Inositol_tetrakis-P_1-kinase.
DR   Pfam; PF05770; Ins134_P3_kin; 1.
DR   PROSITE; PS50975; ATP_GRASP; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding;
KW   Complete proteome; Hydrolase; Isomerase; Kinase; Magnesium;
KW   Metal-binding; Nucleotide-binding; Reference proteome; Transferase.
FT   CHAIN         1    414       Inositol-tetrakisphosphate 1-kinase.
FT                                /FTId=PRO_0000220833.
FT   DOMAIN      117    325       ATP-grasp. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00409}.
FT   NP_BIND     188    199       ATP.
FT   METAL       281    281       Magnesium 1.
FT   METAL       295    295       Magnesium 1.
FT   METAL       295    295       Magnesium 2.
FT   METAL       297    297       Magnesium 2.
FT   BINDING      18     18       1D-myo-inositol 1,3,4-trisphosphate.
FT                                {ECO:0000250}.
FT   BINDING     106    106       ATP.
FT   BINDING     157    157       ATP.
FT   BINDING     167    167       1D-myo-inositol 1,3,4-trisphosphate.
FT                                {ECO:0000250}.
FT   BINDING     199    199       1D-myo-inositol 1,3,4-trisphosphate.
FT                                {ECO:0000250}.
FT   BINDING     214    214       ATP.
FT   BINDING     232    232       ATP.
FT   BINDING     236    236       ATP.
FT   BINDING     297    297       1D-myo-inositol 1,3,4-trisphosphate.
FT                                {ECO:0000250}.
FT   MOD_RES     340    340       N6-acetyllysine; by EP300 and CREBBP.
FT                                {ECO:0000269|PubMed:22308441}.
FT   MOD_RES     383    383       N6-acetyllysine; by EP300 and CREBBP.
FT                                {ECO:0000269|PubMed:22308441}.
FT   MOD_RES     410    410       N6-acetyllysine; by EP300 and CREBBP.
FT                                {ECO:0000269|PubMed:22308441}.
FT   VAR_SEQ     302    314       YEGVSEFFTDLLN -> DCQVCFIEGWKTD (in
FT                                isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_016478.
FT   VAR_SEQ     315    414       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_016479.
FT   MUTAGEN      18     18       K->A: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:15837423}.
FT   MUTAGEN      58     58       H->A: No effect.
FT                                {ECO:0000269|PubMed:15837423}.
FT   MUTAGEN      59     59       K->A: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:15837423}.
FT   MUTAGEN     106    106       R->A: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:15762844,
FT                                ECO:0000269|PubMed:15837423}.
FT   MUTAGEN     157    157       K->A: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:15762844}.
FT   MUTAGEN     162    162       H->Q: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:15837423}.
FT   MUTAGEN     163    163       G->A,P: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:15762844,
FT                                ECO:0000269|PubMed:15837423}.
FT   MUTAGEN     163    163       G->A: No effect.
FT                                {ECO:0000269|PubMed:15762844,
FT                                ECO:0000269|PubMed:15837423}.
FT   MUTAGEN     167    167       H->A,Q: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:15837423}.
FT   MUTAGEN     188    188       Q->A: No effect.
FT                                {ECO:0000269|PubMed:15837423}.
FT   MUTAGEN     193    193       H->A: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:15837423}.
FT   MUTAGEN     199    199       K->A: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:15837423}.
FT   MUTAGEN     212    212       R->A: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:15837423}.
FT   MUTAGEN     214    214       S->A: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:15837423}.
FT   MUTAGEN     215    215       L->A: No effect.
FT                                {ECO:0000269|PubMed:15837423}.
FT   MUTAGEN     281    281       D->A: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:15762844}.
FT   MUTAGEN     295    295       D->A: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:15762844}.
FT   MUTAGEN     297    297       N->A,L: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:15762844,
FT                                ECO:0000269|PubMed:15837423}.
FT   MUTAGEN     297    297       N->D: Induces a strong reduction in
FT                                kinase activity.
FT                                {ECO:0000269|PubMed:15762844,
FT                                ECO:0000269|PubMed:15837423}.
FT   MUTAGEN     301    301       G->A: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:15837423}.
FT   CONFLICT    356    356       S -> N (in Ref. 1; AAC50483).
FT                                {ECO:0000305}.
FT   HELIX         1      5       {ECO:0000244|PDB:2Q7D}.
FT   STRAND        9     13       {ECO:0000244|PDB:2Q7D}.
FT   HELIX        16     22       {ECO:0000244|PDB:2Q7D}.
FT   HELIX        24     32       {ECO:0000244|PDB:2Q7D}.
FT   TURN         33     35       {ECO:0000244|PDB:2Q7D}.
FT   STRAND       37     40       {ECO:0000244|PDB:2Q7D}.
FT   HELIX        48     50       {ECO:0000244|PDB:2Q7D}.
FT   STRAND       54     58       {ECO:0000244|PDB:2Q7D}.
FT   HELIX        61     68       {ECO:0000244|PDB:2Q7D}.
FT   HELIX        72     87       {ECO:0000244|PDB:2Q7D}.
FT   STRAND       91     95       {ECO:0000244|PDB:2Q7D}.
FT   HELIX        97    102       {ECO:0000244|PDB:2Q7D}.
FT   HELIX       106    120       {ECO:0000244|PDB:2Q7D}.
FT   STRAND      130    133       {ECO:0000244|PDB:2Q7D}.
FT   HELIX       138    140       {ECO:0000244|PDB:2ODT}.
FT   HELIX       141    147       {ECO:0000244|PDB:2Q7D}.
FT   STRAND      152    157       {ECO:0000244|PDB:2Q7D}.
FT   TURN        164    167       {ECO:0000244|PDB:2QB5}.
FT   STRAND      168    172       {ECO:0000244|PDB:2Q7D}.
FT   HELIX       175    177       {ECO:0000244|PDB:2Q7D}.
FT   STRAND      185    189       {ECO:0000244|PDB:2Q7D}.
FT   STRAND      196    203       {ECO:0000244|PDB:2Q7D}.
FT   STRAND      206    213       {ECO:0000244|PDB:2Q7D}.
FT   STRAND      228    231       {ECO:0000244|PDB:2Q7D}.
FT   HELIX       232    234       {ECO:0000244|PDB:2Q7D}.
FT   HELIX       243    245       {ECO:0000244|PDB:2Q7D}.
FT   HELIX       259    273       {ECO:0000244|PDB:2Q7D}.
FT   STRAND      277    284       {ECO:0000244|PDB:2Q7D}.
FT   TURN        286    288       {ECO:0000244|PDB:2Q7D}.
FT   STRAND      291    299       {ECO:0000244|PDB:2Q7D}.
FT   HELIX       308    324       {ECO:0000244|PDB:2Q7D}.
SQ   SEQUENCE   414 AA;  45621 MW;  E89E2EE11971278E CRC64;
     MQTFLKGKRV GYWLSEKKIK KLNFQAFAEL CRKRGMEVVQ LNLSRPIEEQ GPLDVIIHKL
     TDVILEADQN DSQSLELVHR FQEYIDAHPE TIVLDPLPAI RTLLDRSKSY ELIRKIEAYM
     EDDRICSPPF MELTSLCGDD TMRLLEKNGL TFPFICKTRV AHGTNSHEMA IVFNQEGLNA
     IQPPCVVQNF INHNAVLYKV FVVGESYTVV QRPSLKNFSA GTSDRESIFF NSHNVSKPES
     SSVLTELDKI EGVFERPSDE VIRELSRALR QALGVSLFGI DIIINNQTGQ HAVIDINAFP
     GYEGVSEFFT DLLNHIATVL QGQSTAMAAT GDVALLRHSK LLAEPAGGLV GERTCSASPG
     CCGSMMGQDA PWKAEADAGG TAKLPHQRLG CNAGVSPSFQ QHCVASLATK ASSQ
//
